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ABSTRACT
Neuroblastoma (NBL) is a childhood malignancy of the sympathetic nervous system. For high-risk NBL
patients, the mortality rate is still over 50%, despite intensive multimodal treatment. Anti-GD2 monoclonal
antibody (mAB) in combination with systemic cytokine immunotherapy has shown clinical efﬁcacy in
high-risk NBL patients. Targeted therapy using histone deacetylase inhibitors (HDACi) is currently being
explored in cancer treatment and already shows promising results. Using our recently developed
transplantable TH-MYCN NBL model, we here report that the HDAC inhibitor Vorinostat synergizes with
anti-GD2 mAb therapy in reducing NBL tumor growth. Further mechanistic studies uncovered multiple
mechanisms for the observed synergy, including Vorinostat-induced speciﬁc NBL cell death and
upregulation of the tumor antigen GD2 on the cell surface of surviving NBL cells. Moreover, Vorinostat
created a permissive tumor microenvironment (TME) for tumor-directed mAb therapy by increasing
macrophage effector cells expressing high levels of Fc-receptors (FcR) and decreasing the number and
function of myeloid-derived suppressor cells (MDSC). Collectively, these data imply further testing of other
epigenetic modulators with immunotherapy and provide a strong basis for clinical testing of anti-GD2 plus
Vorinostat combination therapy in NBL patients.
Abbreviations: ADCC, antibody dependent cellular cytotoxicity; ADCP, antibody dependent cellular phagocytosis;
APC, antigen presenting cell; BMDM, bone marrow derived macrophage; DC, dendritic cells; FcR, Fc-receptor; GD2,
disialoganglioside; HDACi, histone deacetylase inhibitor; mAb, monoclonal antibody; MDSC, myeloid-derived sup-
pressor cell; MHCI, MHC Class I; MHCII, MHC Class II; M-MDSC, monocytic myeloid-derived suppressor cell; NBL, neu-
roblastoma; NK cells, natural killer cells; PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; TIL, tumor
inﬁltrating leukocytes; TME, tumor microenvironment; Treg, T regulatory cell.
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Introduction
NBL is a childhood malignancy of the sympathetic nervous sys-
tem accounting for 12% of cancer-associated deaths in children
under 15 y of age.1 Patients with high-risk NBL, including
MYCN-ampliﬁed NBL, have a poor long-term survival despite
intensive multimodal treatment.2 In a recent phase III clinical
trial, immunotherapy improved the event-free survival of high-
risk NBL patients by around 20%.3 The immunotherapy in this
trial consisted of a tumor-speciﬁc mAb directed toward the
tumor antigen GD2 in combination with administration of
immune stimulating cytokines IL-2 and GM-CSF. FcR express-
ing immune cells, including natural killer (NK) cells, granulo-
cytes and recently also other myeloid cells, have been
implicated as the effector cells in the clinical response following
anti-GD2 mAb.4,5 However, despite the observed clinical bene-
ﬁt using immunotherapy, still about half of the patients show
progressive disease. Therefore, further improvement of NBL
treatment is needed to increase the survival of these pediatric
patients.
One approach to improve NBL treatment efﬁcacy is to com-
bine anti-GD2 mAb immunotherapy with tumor-targeted ther-
apy. The ultimate goal of such an immunocombination therapy
is to induce and boost potent antitumor immunity and to
counteract tumor-induced immune suppression, as reviewed in
ref.6. An emerging tumor-targeting therapy involves the use of
HDACi as epigenetic modulators to eliminate and modulate
tumor cells.7 HDAC inhibition results in increased acetylation
of histone proteins leading to changes in gene expression.8
HDACi target multiple cellular processes simultaneously and
also impact normal cells, although tumor cells appear much
more sensitive.9 Speciﬁcally in cancer cells, the altered gene
expression leads to activation of and sensitization to intrinsic
and extrinsic apoptosis pathways.10 Besides targeting histone
proteins, HDACi also induce hyperacetylation of pro-apoptotic
cytosolic proteins like p53, thereby also inducing tumor cell
death.11 The classical HDACi block the function of one or
more of the 11 classical zinc-containing HDAC enzymes.
Among the zinc-containing HDACs are the class-I HDAC
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(HDAC 1,2,3, and 8) and class-II HDAC (HDAC 4,5,6,7,9,10)
enzymes.12 Class speciﬁc HDACi inhibit HDAC from either
class, while panHDACi inhibit HDACs from both classes. Vari-
ous panHDACi are currently in phase I–III trials for the treat-
ment of cancer.13,14
To design novel strategies that combine immunotherapy
with tumor targeted therapies, we generated a transplantable
autologous NBL model derived from the TH-MYCN transgenic
mouse. The MYCN proto-oncogene is frequently ampliﬁed on
the genomic level in NBL, a phenomenon associated with an
adverse prognosis.15,16 The TH-MYCN transgenic mouse
model is driven by over expression of N-MYC in developing
sympathetic nervous cells and closely resembles high-risk
human NBL.17,18 Using our transplantable TH-MYCN model
in C57Bl/6 mice, we found that the immunobiology of this
model was highly similar to human NBL, including endoge-
nous expression of the tumor surface antigen GD2.19 Moreover,
similar to NBL in patients, the NBL tumors arising in the TH-
MYCN NBL model were highly inﬁltrated by myeloid cells,
including macrophages and MDSC, suggestive for an important
role in NBL pathogenesis.19-21 Macrophages in tumors are gen-
erally classiﬁed as either antitumor M1 or pro-tumor M2 mac-
rophages.22,23 MDSC are immature myeloid cells that
accumulate in tumors and can mediate potent local and sys-
temic immune suppression.24
In the current study, we report that anti-GD2 mAb therapy
combined with the HDACi Vorinostat results in synergistic anti-
tumor effects in this novel NBL mouse model. As part of the
explanation of this synergy, we uncovered that TH-MYCN NBL
cells were highly sensitive to HDACi-mediated cell death, while
surviving NBL cells upregulated the tumor antigen GD2. Fur-
thermore, Vorinostat treatment altered the composition and
function of myeloid cells in NBL tumors, resulting in myeloid
cells expressing less immune suppressive genes and more activat-
ing FcR. Our study provides a rationale for clinical testing of
GD2 mAb plus Vorinostat combination therapy in NBL patients.
Results
TH-MYCN NBL cells are highly sensitive to HDACi-mediated
cell death
To determine whether the murine TH-MYCN cell lines 9464D
and 975A2 were sensitive to HDACi-mediated cell death, these
cells were exposed to increasing concentrations of various
HDACi, after which viability was determined via standard
MTT metabolic activity assays. For comparison, the MYCN-
negative NBL Neuro-2a, the glioblastoma GL261 and the ﬁbro-
sarcoma 3T3 cell lines were used. TH-MYCN Mycn-transgenic
9464D and 975A2 NBL cells, incubated with the panHDACi
Vorinostat, Givinostat, Belinostat and PCI-24781, showed a
signiﬁcantly stronger reduction in metabolic activity and hence
in viability compared to the non-MYCN NBL cell line Neuro-
2a and the other non-NBL cell lines GL261 and 3T3 (Fig. 1).
Subsequent analysis revealed that the 9464D and 975A2 NBL
cells were also more sensitive for the class-I speciﬁc HDACi
Entinostat and a HDAC1,2 speciﬁc HDACi compared to the
control cell lines (Fig. 1). In contrast, the class-II HDACi Tuba-
cin and a HDAC6 speciﬁc HDACi had little impact on either
the TH-MYCN cells or the control tumor cell lines (Fig. 1).
The half maximal inhibitory concentrations (IC50) for the dif-
ferent HDACi and cell lines tested are depicted in Table 1.
These IC50 values and 95% conﬁdence intervals demonstrate
that the murine TH-MYCN NBL cells are highly sensitive to
pan- and class-I HDACi when directly compared to other non-
NBL murine cancer cell lines and the non-MYCN NBL cell line
Neuro-2a.
Anti-GD2 mAb plus vorinostat combination therapy is
synergistic in reducing NBL growth
Next, we determined the effect of anti-GD2 mAb treatment
alone or in combination with HDACi treatment at stringent
therapeutic conditions in vivo. We selected the panHDACi
Vorinostat for these studies as it strongly reduced the viability
of 9464D NBL cells and has entered phase I clinical trials in
pediatric oncology patients, including NBL patients (www.clini
caltrials.gov).14 Mice bearing established 9464D NBL tumors
were treated with anti-GD2 mAb or Vorinostat alone and with
the combination of both. Anti-GD2 mAb monotherapy was
initiated on day 8 following tumor inoculation and was
repeated twice weekly until day 43. In this stringent therapeutic
model, anti-GD2 mAb treatment alone, starting on day 8 post-
inoculation, had no or very little impact on tumor growth rela-
tive to isotype control Ab (Fig. 2). As we recently reviewed,
pre-activated effector immune cells are further enhanced in
their function by HDAC inhibitors, providing a rationale to ini-
tiate HDAC inhibitor therapy after immunotherapy.25 There-
fore, we started Vorinostat treatment after anti-GD2 therapy in
our experiments. I.p. injections of Vorinostat (150 mg/kg) were
administered daily for 3 consecutive days and this treatment
schedule was repeated weekly, until day 45. Vorinostat mono-
therapy caused a signiﬁcant reduction in tumor growth com-
pared to PBS/DMSO control treatment (Fig. 2). Interestingly,
the combination of Vorinostat plus anti-GD2 mAb therapy
resulted in a synergistic reduction of tumor growth in this ther-
apeutic setting (Fig. 2). On day 45, the last day of the combina-
tion treatment, all (9/9) mice in the anti-GD2 plus Vorinostat
combination group versus 4/9 mice in the Vorinostat mono-
therapy group were still alive. We concluded that the combina-
tion of anti-GD2 mAb-based immunotherapy and targeted
therapy using Vorinostat-reduced NBL tumor growth in a syn-
ergistic manner.
Vorinostat increases GD2 expression on NBL cells and anti-
GD2 mAb mediated killing
To uncover the mechanisms responsible for the observed syn-
ergy of anti-GD2 mAb plus Vorinostat combination therapy in
vivo, we ﬁrst investigated the effect of Vorinostat on the expres-
sion of immune relevant antigens on surface of the tumor cells
in vitro. Hereto, tumor cells were exposed for 18 h to Vorino-
stat in concentrations which affected viability only mildly, max-
imally 20%. The data revealed that Vorinostat treatment
upregulated MHC class I (MHCI), but not MHC class II
(MHCII) expression, on surviving 9464D NBL and B16F10
melanoma cells (Fig. 3A). The expression of other immune-
related molecules tested, including the NK cell activating
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ligands Rae1 and Mult-1 as well as the co-inhibitory molecule
PD-L1, was not altered following HDACi exposure (data not
shown).
Next, we determined whether the expression of the GD2
antigen itself was affected by Vorinostat treatment. As previ-
ously reported, 9464D NBL cells shows a population with an
upregulated expression of GD2 and a population with a very
high expression of GD2 (Fig. 3B).26 Strikingly, Vorinostat
increased GD2 expression in both populations of the murine
9464D as well as in human IMR-32 NBL cells, resulting in a
more than 150% increase in the Mean Fluorescent Intensity of
GD2 compared to control treated cells (Figs. 3B and C). We
Figure 1. Neuroblastoma cells are sensitive to HDACi-mediated cell death. (A) TH-MYCN derived 9464D and 975A2 neuroblastoma cells, Neuro-2a neuroblastoma, GL261
glioblastoma and 3T3 ﬁbrosarcoma cells were incubated for 36 h with 32, 256, 2048 and 16384 nM of the indicated HDACi. Following a 36 h incubation, standard MTT
assays were performed, metabolic activity was compared to control treated cells and plotted in dose response curves (p < 0.05 for 9464D or 975A2 vs. Neuro-2a or
GL261 or 3T3). Representative graphs of three independent experiments are shown.
Table 1. IC50s (in nM) for the various HDACi and cell lines are depicted with corresponding 95% conﬁdence intervals.
GL261 3T3 Neuro-2a 9464D 975A2
Vorinostat >16,000 3,535 (2,175–5,745) 1,446 (882–2,372) 608 (540–683) 657 (446–969)
Givinostat >16,000 5,111 (3,122–8,368) 2,426 (1,603–3,671) 1504 (1,207–1,874) 980 (753–1,275)
Belinostat >16,000 627 (396–992) 579 (482–695) 84 (54–130) 58 (47–71)
PCI-24781 >16,000 363.7 (225–587) 406 (208–794) 138 (96–199) 89 (79–102)
Entinostat >16,000 >16,000 13,453 (6,941–26,075) 2,997 (2,245–4,000) 1,001 (555–1,804)
HDAC1,2 >16,000 587 (360–957) 408 (184–903) 468.5 (393–558) 194.8 (141–297)
Tubacin 9,362 (5,416–16,085) 7,207 (4,710–11,029) 4,064 (6,010–22,358) 9,710 (4,222–22,382) 2,737 (2,198–3,408)
HDAC6 >16,000 9,948 (4,925–20,093) 4,807 (2,182–10,591) 10,837 (3,584–12,652) 4,099 (1,830–6,459)
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also observed a dose dependent upregulation of GD2 by the
panHDACi Givinostat, the class-I inhibitor Entinostat and a
HDAC1,2 speciﬁc inhibitor (Fig. 3C). In contrast, GD2 levels
were not increased by the class-II HDACi Tubacin or a
HDAC6 speciﬁc inhibitor (Fig. 3C). Next, the effect of increas-
ing concentrations of Vorinostat on the transcription of GD2
Synthase, an essential gene for GD2 expression, was assessed
using qPCR.27,28 No signiﬁcant changes were observed in GD2
Synthase mRNA levels in 9464D cells following Vorinostat
treatment (Fig. 3D, left). Vorinostat exposure, however, did
result in increased GD2 Synthase protein levels in a dose-
dependent manner (Fig. 3D, right).
To determine the functional consequences of increased GD2
expression, 9464D cells were treated with Vorinostat or control
for 24 h, washed and subsequently co-cultured with immune
effector cells in the presence of anti-GD2 mAb or an isotype
control Ab. As effector cells, BM derived macrophages
(BMDM) treated with or without IL-4 and NK/LAK cells were
used. Addition of IL-4 upregulated CD206 and FcRy1/3 expres-
sion in BMDM, suggestive of an M2-like phenotype with
enhanced phagocytic capacity (Fig. 3E).29,30 Vorinostat pre-
treated tumor cells were not killed more efﬁciently by BMDM
or NK cells relative to control treated tumor cells (Figs. 3F,G).
Addition of anti-GD2 mAb, but not isotype control mAb, how-
ever, resulted in signiﬁcantly enhanced killing of the Vorinostat
pre-treated tumor cells relative to control cells irrespective of
the type of immune effector cell (Figs. 3F,G). Interestingly, IL-4
treated, M2-like BMDM mediated anti-GD2 mAb mediated
killing of Vorinostat pre-treated tumor cells even at low effector
: target ratio’s (Fig. 3F, right). Collectively, these data indicate
that Vorinostat treatment of NBL cells enhanced GD2
expression on NBL cells, resulting in more efﬁcient anti-GD2
mAb-mediated tumor cell killing by NK cells, macrophages
and especially M2-like macrophages.
Vorinostat increases GD2 expression and affects the
composition of tumor myeloid cells
To determine whether Vorinostat could also increase GD2
expression in vivo, mice-bearing NBL tumors were treated with
Vorinostat or DMSO/PBS control. Similar to our in vitro obser-
vations, GD2 expression on tumors was signiﬁcantly increased
following Vorinostat treatment as measured by FACS (Fig. 4A)
and immunohistochemistry (Fig. 4B). Vorinostat treatment
also seemed to upregulate the expression of MHCI on the
tumor cells in vivo, but this did not reach statistical signiﬁcance
(Fig. 4A).
Effects of Vorinostat on tumor cells have been extensively
studied, but much less are known regarding its effect on
immune cell inﬁltration and function in tumors in vivo. There-
fore, we determined the presence and phenotype of immune
cells in the NBL TME following Vorinostat treatment. Percen-
tages of CD45.2C tumor inﬁltrating leukocytes (TIL) within the
total tumor cell suspension were unaltered in Vorinostat and
control treated tumors (Fig. 5A). Within these CD45.2C TIL,
the percentages of CD3CCD4C and CD3CCD8C T cells,
CD3¡NK1.1C NK cells and CD11bC myeloid cells were all very
similar in Vorinostat and control treated tumors (Fig. S1A and
Fig. 5B). T cell subset analysis revealed that also the level of
CD4CFoxP3C Treg within the CD4C T cell population was not
affected by Vorinostat treatment (Fig. S1B).
Analysis of the tumor inﬁltrating CD45.2CCD11bC myeloid
cells showed a signiﬁcant increase in the percentage of
CD11cdimF4/80highMHCIIint macrophages upon Vorinostat
treatment (Fig. 5C). In contrast, there was a strong decrease in
the CD11clowF4/80lowMHCIIlow non-APC, while the percentage
of CD11chighF4/80dimMHCIIhigh DC was not altered (Fig. 5C).
These data indicate the presence of more macrophages in NBL
tumors following Vorinostat treatment. Strikingly, these mac-
rophages expressed high levels of FcRy1 and FcRy2/3 resulting
in a signiﬁcantly increased expression of these FcR in the total
CD45CCD11bC myeloid population (Fig. S2 and Fig. 5D). The
CD11cdimF4/80highMHCIIint macrophages after Vorinostat
treatment showed increased surface expression of CD206 and
CD80, while expression of MHCII was signiﬁcantly decreased
(Fig. S3). These data suggest a mixed M1/M2 phenotype of
these tumor macrophages following Vorinostat treatment.
We next analyzed the tumor-inﬁltrating myeloid cells using
mAbs directed toward the markers Ly-6C and Ly-6G to dis-
criminate between polymorphonuclear MDSC (PMN-MDSC)
and monocytic MDSC (M-MDSC), respectively.31 Strikingly,
CD11cnegLy-6ChighLy-6GnegMHCIIlow cells with a phenotype
corresponding to M-MDSC were largely depleted from Vorino-
stat treated tumors (Fig. 5E). The percentage of CD11cint/
highLy-6CnegLy-6GnegMHCIIint/high cells with a phenotype cor-
responding to APC was increased, while the percentage of
CD11clow/intLy-6CdimLy-6GhighMHCIIlow cells corresponding
to PMN-MDSC was unaltered (Fig. 5E). Thus, Vorinostat treat-
ment signiﬁcantly changes the composition of the tumor-inﬁl-
trating myeloid cells in these NBL tumors, resulting in more
Figure 2. Anti-GD2 mAb and Vorinostat mediate synergistic anti-NBL effects in
vivo. Immunocombination therapy using anti-GD2 mAb and Vorinostat results in
synergistic inhibition of NBL tumor growth. (A) Mice were inoculated s.c. with 1 £
106 9464D cells on day 0. Anti-GD2 mAb therapy (200 mg/mouse, i.p.) was initiated
on day 8 and repeated twice weekly. Vorinostat treatment (150 mg/kg, i.p.) was
initiated on day 14 and given for 3 consecutive days and this scheme was repeated
weekly until day 45. Tumor growth was monitored and tumor volumes were calcu-
lated. Occasionally (< 5% of all mice), tumors caused skin ulceration which was
randomly divided over the treatment groups; these mice were sacriﬁced and
excluded from the analysis. Mean tumor volumes for each treatment group (9
mice/group) are depicted (#p < 0.05 for isotype or anti-GD2 vs. Vorinostat or Vori-
nostat C anti-GD2) (p < 0.05 for Vorinostat vs. Vorinostat C anti-GD2). On day
45, 9/9 mice of the anti-GD2 plus Vorinostat group, whereas 4/9 mice of the Vori-
nostat monotherapy group were still alive (deﬁned by tumor volume <
1000 mm3). Representative data of two independent are shown.
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macrophages showing a mixed M1/M2 phenotype and less M-
MDSC.
Vorinostat creates a more permissive TME for tumor-
directed mAb therapy
To determine the functional consequences of Vorinostat treat-
ment on the tumor-inﬁltrating myeloid cells in NBL tumors,
myeloid cells were isolated from tumors of mice treated with
Vorinostat or control. First, CD45.2C TIL from pooled tumor
cell suspensions of 18 mice per treatment arm were isolated
using MACS. Next, the CD45.2CCD11bC myeloid cells were
puriﬁed to homogeneity by FACsort and directly lysed for
RNA extraction. RT-qPCR analysis of the house keeping genes
Gusb and Pbgd relative to each other showed unaltered expres-
sion levels for control and Vorinostat treated samples, indicat-
ing these housekeeping genes could be used for relative gene
expression analysis following Vorinostat treatment (Fig. S4).
To better understand the nature of the Vorinostat-induced
myeloid cells in NBL tumors, the expression of commonly used
macrophage markers was determined. The transcript levels of
the M2 macrophage markers Cd206, Cd163, Il4ra were all
increased, whereas the levels of M2 markers Fizz1 and Ym1,
were decreased in the tumor-inﬁltrating myeloid cells following
Vorinostat, suggesting a mixed M1/M2 macrophage phenotype
(Fig. 6A). In addition, we determined the expression of several
cytokines by the tumor myeloid cells following Vorinostat
treatment. Expression of the M2-associated cytokine TGF-b
was not altered following Vorinostat treatment, whereas the
M2-associated cytokine IL-10 was signiﬁcantly increased
(Fig. S5). The M1-associated cytokines TNF-a and IL-6 were
both signiﬁcantly decreased (Fig. S5). These data are in line
with the aforementioned FACS data comparing control versus
Vorinostat-induced macrophages (Fig. S3).
Next, we determined the expression of genes related to mye-
loid cell function, like FcR essential for ADCC and immuno-
suppressive mediators. The FACS analysis already revealed a
signiﬁcant increase in the levels of FcRy1 and FcRy2/3
expressed on CD45.2CCD11bC myeloid cells in the tumor
(Fig. 5D). The latter mAb, however, recognizes both FcRy2b
and FcRy3, and does not discriminate between inhibiting and
activating FcR.32-34 Vorinostat treatment induced an increase
in mRNA levels of the activating, low-afﬁnity Fcrg3, while
expression of the inhibitory, low-afﬁnity Fcrg2b was not altered
(Fig. 6B). Moreover, the high-afﬁnity, transcripts of the activat-
ing receptors Fcrg1 and Fcrg4 were both increased in the tumor
inﬁltrating myeloid cells upon Vorinostat treatment (Fig. 6B).
In addition, transcript levels of four genes directly involved in
immune suppression, Arginase, S100a8, S100a9 and Pdl1, were
all strongly decreased in the myeloid cells of Vorinostat treated
Figure 3. HDACi increase GD2 expression by NBL cells resulting in increased anti-GD2 mAb-mediated killing. (A) Expression of MHCI and MHCII by 9464D and B16F10 cells
following incubation with 256 nM Vorinostat or control for 18 h. Gray shading D isotype control, Thin line D control treated, Thick line D Vorinostat treated. Representa-
tive data from three independent experiments are shown. (B) Expression of GD2 by 9464D and IMR-32 cells after incubation with 2.5 mM and 256 nM Vorinostat, respec-
tively, for 18 h. Gray shading D isotype control, Thick line D speciﬁc staining. Representative data from three independent experiments are shown. (C) Expression of GD2
relative to control by 9464D and IMR-32 cells after incubation with the indicated HDACi for 18 h. Mean Fluorescence Intensity (MFI) of GD2 is depicted. Pooled data from
three independent experiments are depicted (p < 0.05, p < 0.01). (D) 9464D cells were exposed to indicated concentrations of Vorinostat for 24 h after which cells
were lysed and analyzed by qPCR (left) and Western Blot (right) for expression of GD2 Synthase (p < 0.05, p < 0.01). Representative data from two independent
experiments are depicted. (E) Day 6 BMDM were treated with 20 ng/mL IL-4 for 24 h and analyzed for the expression of CD86, MHCII, CD206 and FcRg2/3. Pooled data
from two independent experiments are depicted (p < 0.05). (F,G) Treatment of 9464D cells with Vorinostat increases anti-GD2 mAb mediated killing. 9464D cells were
incubated for 18 h with 256 nM Vorinostat or control and then co-cultured with indicated effector cells in the presence of isotype control Ab or anti-GD2 mAb (p < 0.05,
p < 0.01, p < 0.001). Representative data from 2–3 independent experiments for each immune effector cell type are shown.
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tumors (Fig. 6C).31 In agreement with the reduced expression
of these immunosuppressive genes, the markers Cd49d and
Ly6c, expressed mainly by immunosuppressive M-MDSC, were
also expressed to a much lesser extent in the myeloid compart-
ment of Vorinostat treated tumors (Fig. 6D).35,36 Collectively,
these data indicate that Vorinostat treatment creates an
immune permissive TME for tumor-directed mAb therapy in
NBL tumors.
Discussion
Here, we report that anti-GD2 mAb plus Vorinostat combina-
tion therapy mediates synergistic antitumor effects in a novel
autologous NBL mouse model. As an explanation for this syn-
ergy, we uncovered that TH-MYCN transgenic NBL cells were
highly sensitive to HDACi-mediated cell death. In addition, the
HDACi Vorinostat upregulated the GD2 antigen on surviving
NBL cells resulting in enhanced anti-GD2 mAb mediated kill-
ing. Finally, Vorinostat treatment completely altered the NBL
TME, resulting in more macrophages expressing activating FcR
and less M-MDSC expressing immune suppressive genes.
These mechanistic insights into anti-GD2 plus Vorinostat com-
bination therapy provide a rationale for clinical testing of this
combination therapy in NBL patients.
Over the past decade, several tumor-targeted mAbs were
shown to induce clinical responses.6,37 Durable clinical
responses following tumor-speciﬁc mAb therapy, however,
are observed in only 10–30% of cancer patients.38 Previ-
ously, we observed an initial delay in the outgrowth of NBL
tumor upon GD2 mAb therapy in our transplantable model,
but in the current more stringent setting no signiﬁcant
delay in overall survival was observed.19 Similar to these
observations in mice, anti-GD2 mAb therapy alone did not
have a major clinical effect in NBL patients when combined
with Retinoic Acid therapy, a vitamin A metabolite induc-
ing NBL differentiation.39 Anti-GD2 mAb plus systemic
cytokines IL-2 and GM-CSF and retinoic acid therapy, how-
ever, resulted in a 20% improved 5 y survival.3 We now
show that the efﬁcacy of anti-GD2 mAb therapy for NBL in
mice is also enhanced by addition of the HDACi Vorino-
stat. Interestingly, the combination of the panHDACi Val-
proic acid and Retinoic Acid was previously shown to
induce synergistic NBL differentiation and apoptosis.40
Therefore, it will be extremely interesting to determine how
addition of epigenetic modulators will affect the efﬁcacy of
anti-GD2 mAb therapy plus Retinoic Acid/IL-2/GM-CSF
combination therapy. Vorinostat combined with Retinoic
Acid caused grade 3 hematologic toxicity at maximum in
the six evaluated patients in a phase I trial, whereas sys-
temic IL-2 and GM-CSF administration caused grade 3 to 4
capillary leak syndrome and hypotension in around 20%
and 10% of patients. Because of these apparent different
toxicity proﬁles, it may also be important to explore
Figure 4. Vorinostat increases GD2 expression by NBL cells in vivo. (A) Mice bearing 9464D tumors (6 mice/group) were treated with Vorinostat (150 mg/kg) for 3 conse-
cutive days. One day after the last injection tumors were excised and single-cell suspensions were made. Expression of MHCI and GD2 was determined on the CD45.2¡
tumor cells for Vorinostat and control tumors (p < 0.05). Representative data from three independent experiments. (B) Cryo-sections of 9464D tumors treated with Vori-
nostat or control were stained using isotype control Ab or anti-GD2-Cy5 mAb. Representative data from two independent experiments are presented.
e1164919-6 M. KROESEN ET AL.
Vorinostat plus anti-GD2 mAb combination therapy in the
absence of systemic cytokine administration.3,14
As an explanation for the synergy of Vorinostat plus
anti-GD2 mAb combination therapy, we found novel effects
of Vorinostat treatment on NBL cells and immune cells in
vivo. MYCN transgenic NBL cells were highly sensitive for
panHDACi and Class-I HDACi. One possible explanation
for this high sensitivity are the reported interactions of N-
MYC with several class-I HDACs.41,42 In addition to induc-
ing efﬁcient NBL cell death, Vorinostat treatment increased
the expression of the tumor antigen GD2 on surviving NBL
cells, resulting in enhanced anti-GD2 mAb-mediated tumor
cell killing in vitro. How Vorinostat treatment affects GD2
expression levels is not yet clear. The ﬁnding that Vorino-
stat did not induce signiﬁcant changes in GD2 Synthase
mRNA levels in 9464D cells, but did increase GD2 Synthase
protein levels, implies that Vorinostat either acts via
affecting the direct acetylation of GD2 Synthase or indi-
rectly via (transcriptional) regulation of GD2 Synthase (de)
stabilizing genes.
Figure 5. Vorinostat treatment increases the presence of macrophages while reducing M-MDSC in the TME of NBL tumors. Mice bearing 9464D tumors (6 mice/group)
were treated with Vorinostat (150 mg/kg) for 3 consecutive days after which tumors were excised and single-cell suspensions were made. (A) Vorinostat does not alter
total leukocyte inﬁltration of NBL tumors. The total tumor cell suspension was analyzed for the presence of CD45.2C leukocytes. Representative data from three indepen-
dent experiments. (B) Vorinostat does not alter myeloid cell presence in spleens and tumors. CD45.2C leukocytes were gated and analyzed for the expression of CD11b.
Representative data from three independent experiments are shown. (C) Vorinostat increases the presence of macrophages within the tumor inﬁltrating myeloid cells.
CD45.2CCD11bC tumor-inﬁltrating myeloid cells were gated and analyzed for the expression of CD11c, F4/80 and MHCII. Percentages of CD11cdimF4/80highMHCIIint macro-
phages, CD11chighF4/80dimMHCIIhigh DC and CD11clowF4/80lowMHCIIlow non-APC are depicted (p < 0.05, p < 0.001). Representative data from three independent
experiments are presented. (D) Vorinostat upregulates the expression of FcRg1 and FcRg2/3 on the cell surface of tumor-inﬁltrating myeloid cells. CD45.2CCD11bC mye-
loid cells were gated and analyzed for the expression of FcRg1 and FcRg2/3 (p< 0.05, p< 0.01). Representative data from three independent experiments. (E) Vorino-
stat reduces M-MDSC within the tumor-inﬁltrating myeloid cells. CD45.2CCD11bC myeloid cells were gated and analyzed for the expression of CD11c, Ly-6C, Ly-6G and
MHCII. Percentages of and CD11cnegLy-6ChighLy-6GnegMHCIIlow M-MDSC, CD11clow/intLy-6CdimLy-6GhighMHCIIlow PMN-MDSC and CD11cint/highLy-6CnegLy-6GnegMHCIIint/high
APCs are depicted (p < 0.05; p< 0.001). Representative data from three independent experiments are shown.
Figure 6. Vorinostat treatment results in a TME-containing myeloid cells expressing more activating FcR and less immune suppressive genes. (A–D) Mice (18 mice/group)
bearing 9464D tumors were treated with Vorinostat (150 mg/kg) for 3 consecutive days. One day after the last injection tumors were excised and single-cell suspensions
were made and pooled. CD45.2C TILs were isolated from the pooled tumor cell suspensions by CD45.2C MACS separation. The CD45.2CCD11bC cells were subsequently
FACS-sorted and directly lysed for RNA isolation. Following cDNA synthesis, qPCR analysis was performed in triplicate and mRNA expression levels relative to Pbgd were
determined for the indicated genes. mRNA expression relative to Pbgd of the treatment groups were normalized to control samples and are presented as fold-change rel-
ative to control (p < 0.05, p < 0.01, p < 0.001).
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Immune suppressive Treg and MDSC can hamper the
function of immune effector cells in tumors.43 Several pan-
HDACi were previously shown to increase the number and
function of immune suppressive Treg.44,45 Following our
Vorinostat treatment regimen, we did not observe increased
Treg numbers. Vorinostat rather seemed to decrease FoxP3
expression levels in Treg, a phenomenon previously
reported for the class-I HDACi Entinostat (Fig. S1C).46
MDSC are immature myeloid cells that can actively inhibit
antitumor immune responses and accumulate in NBL
tumors in TH-MYCN transgenic mice.20,21,24,36,47 Our
experiments now show that Vorinostat treatment essentially
eliminates the presence of M-MDSC from these NBL
tumors. Moreover, Vorinostat treatment reduced levels of
Arginase and many other genes implicated in M-MDSC-
mediated immune suppression within the CD45CCD11bC
NBL tumor-inﬁltrating myeloid cells. These data are there-
fore indicative for diminished tumor immune suppression
as a consequence of Vorinostat treatment.36,48
FcR expressing immune effector cells are highly important
for the clinical response following tumor-directed mAb ther-
apy, including anti-GD2 mAb therapy.4,5,49,50 We did not
observe differences in the number of NK cells inﬁltrating NBL
tumors after Vorinostat treatment (Fig. S1A). We, however, did
observe increased numbers of macrophages in NBL tumors,
expressing high levels of the activating FcRy1 and FcRy2/3 on
their cell surface following Vorinostat treatment. Expression of
the activating receptors Fcrg1, Fcrg4 and Fcrg3, but not the
inhibitory receptor Fcrg2b, was also increased at the mRNA
level.
Analysis of the macrophage type induced by Vorinostat
treatment revealed a mixed M1/M2 macrophage gene signa-
ture as well as surface and cytokine expression proﬁle.
Although M2 type macrophages in NBL tumors were previ-
ously associated with an adverse disease outcome, tumor-
inﬁltrating macrophages as a whole were repeatedly shown
to be important immune effector cells, especially following
tumor-directed mAb therapy.51-54 In addition, recent
expression proﬁling studies indicate that the M1 and M2
division for macrophages is a serious oversimpliﬁcation of
the complexity of macrophage subtypes and functions in
tumors.22,23 Our data and other studies support that at least
part of the M2 macrophage characteristics are not by
default negative for cancer therapy, and may even be neces-
sary for effective antitumor mAb therapy.30
Overall, our data imply that enhanced expression of
GD2, lower numbers of immune suppressive M-MDSC and
higher numbers of FcRhigh-expressing macrophages in the
tumor all contribute to the efﬁcacy of the Vorinostat plus
anti-GD2 mAb combination therapy. Further support for
these immune effects of Vorinostat is provided by our pre-
liminary data showing enhanced capacity of total CD45.2C
TIL present in Vorinostat treated tumors to eliminate
9464D tumor cells relative to the total TIL isolated from
control tumors.
The synergy of anti-GD2 mAb therapy with Vorinostat
reported here, may have important implications for NBL
patients. As both anti-GD2 mAb plus cytokine treatment and
Vorinostat therapy are applied in pediatric oncology patients,
our study provides a rationale for immunocombination treat-
ment with Vorinostat and anti-GD2 mAb therapy in the treat-
ment of NBL patients.14
A few studies have now reported on successful combi-
nations of HDACi with immunotherapy.46,55,56 One aspect
that deserves further study is the optimal timing of
HDACi treatment in immunocombination therapy, as this
may critically determine the efﬁcacy in vivo.46 In our
experiments, anti-GD2 mAb was administered prior to
Vorinostat. Whether this order of administration is crucial
for the observed synergy in anti-GD2 mAb plus Vorinostat
combination therapy and whether the same order is
required for T-cell-based immunotherapies remains to
investigated.
Materials and methods
Animals and cell lines
Six–eight weeks old female C57Bl/6 wild-type (WT) mice held
under speciﬁed pathogen-free conditions in the Central Animal
Laboratory (Nijmegen, the Netherlands) were purchased from
Charles River (Sulzfeld, Germany). All experiments were per-
formed according to the guidelines for animal care of the Nij-
megen Animal Experiments Committee. GL261 cells were
provided by U. Herrlinger (Bonn, Germany) in 2006 and were
not re-authenticated by the author. IMR-32, Neuro-2a, 3T3
and B16F10 cell lines were obtained from and authenticated by
ATCC (CCL-127, CCL-131, CRL-1658, CRL-6475, respec-
tively) (Manassas, VA). 9464D and 975A2 cells were derived
from spontaneous tumors from TH-MYCN transgenic mice on
C57Bl/6 background and were a kind gift from Dr Orentas in
2010 (NIH, Bethesda) and were authenticated by the author
last in 2013 by qPCR using primers against NBL speciﬁc genes,
including Mycn and GD2 synthase. All cell lines were initially
grown and multiple aliquots were cryopreserved and used
within 6 mo after resuscitation and tested for mycoplasma
using a mycoplasma detection kit (Lonza, Basel, Switzerland).
The hybridoma 14.g2a producing a mouse IgG2a mAb speciﬁc
for GD2 was a kind gift from Dr Reisfeld (Scripps, La Jolla).
B16F10 cells were cultured in Minimal Essential Medium
(MEM) containing 5% fetal bovine serum (FBS, Greiner Bio-
one, Alphen a/d Rijn, the Netherlands), 1% non-essential
amino acids (NEAA) (Invitrogen), 0.5% antibiotic-antimycotic
(AA) (Gibco), 1% pyruvate (Gibco), 2% NaH2CO3 (Gibco),
1.5% MEM Vitamins (Gibco) and 0.05% b-mercaptoethanol.
GL261 cells were cultured in Iscove’s Modiﬁed Dulbecco’s
Medium (IMDM) (Gibco) containing 10% FCS, 1% NEAA,
0.5% AA and 0.05% b-mercaptoethanol. Neuro-2a, IMR-32,
9464D, 975A2 and 3T3 cell lines were cultured in Dulbecco’s
modiﬁed Eagle (DMEM) medium containing 10% FCS, 1%
NEAA, 0.5% AA and 0.05% b-mercaptoethanol.
HDACi
HDACi were purchased from SelleckChem, Houston, USA. An
HDAC1,2 speciﬁc HDACi was synthesized similar to com-
pound 5a in ref.57. The HDAC6-speciﬁc HDACi was synthe-
sized similar to compound 7 in ref.58. All HDACi were
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dissolved in DMSO to a ﬁnal concentration of 5 mM. For in
vivo studies Vorinostat was dissolved in DMSO/PBS 50 mg/mL.
Tumor induction
For induction of tumors, 1 £ 106 9464D cells were injected s.c.
in 50 mL PBS on the right ﬂank of mice. Tumor cell viability
before injection was >95%. As determined by Trypan Blue
staining. Tumor growth was measured every 3–4 d using cali-
pers. Tumor volume was calculated with the formula: (A £ B2)
£ 0.4 in which A is the largest and B is the shortest dimension.
Anti-GD2 mAb and vorinostat treatment in vivo
Anti-GD2/control treatment started on day 8 following tumor
inoculation by i.p. injection of 200 mg mAb and was repeated
twice weekly until day 43. Vorinostat treatment started on day
14 following tumor inoculation by injecting 150 mg/kg Vorino-
stat or DMSO/PBS control i.p. for 3 consecutive days and was
repeated every week until day 45.
Vorinostat treatment and single-cell suspensions
Mice bearing 9464D tumors of 300–600 mm3 were injected i.p.
with 150 mg/kg Vorinostat or DMSO/PBS for 3 consecutive
days. Tumors excised one day following the last injection, were
mechanically dissociated, and enzymatically digested with
1 mg/mL collagenase Type III (Worthington) and 30 mg/mL
DNAse type I (Roche) for 1 h at 37C. EDTA was added to
12.5 mM and fragments were passaged over 100 mm cell
strainers. For GD2 staining ex vivo, cell suspensions were
washed with PBS to decrease background staining.
Antibodies and ﬂow cytometry
Anti-GD2 (clone 14.g2a) mAb was puriﬁed and ﬁlter sterilized
in PBS. Total mouse IgG control Ab was obtained from Jackson
Immunoresearch. Directly labeled mAbs used for staining were
CD11b-A700 (M1/70), H-2Kb/H-2Db-PE (28-8-2006), F4/80-
PE-Cy7 (BM8), CD11c-PerCP (N418), CD4-PerCP (L3T4), Ly-
6G-PE-Cy7 (1A8), CD64-PE (X54-5/7.1), CD16/CD32-A647
(2.4G2), CD206-APC (MR5D3) from Biolegend, CD45.2-FITC
(104), CD11c-APC (HL3), NK1.1-PE (PK136), Ly-6C-PE (AL-
21) and CD3-APC (145-2C11) from BD, MHC II-PE (M5/
114.15.2) and FoxP3-PE-Cy7 (FJK-16s) from eBioscience,
CD8-A700 (53–6.7) from Exbio. Cells for staining were washed
in PBS, incubated with Viability Dye eFluor 780 (eBioscience),
resuspended in PBA, transferred to a V-bottom 96-wells plate
and stained using speciﬁc mAb or the appropriate isotypes.
Cells analyzed on a Cyan apparatus (Beckman Coulter) using
Summit software.
CD45.2CMACS and FACSort
Mice (18 mice/group) bearing 9464D tumors were treated i.p.
with 150 mg/kg Vorinostat or DMSO/PBS for 3 consecutive
days. Tumors excised one day following the last injection and
pooled single-cell suspensions were resuspended in MACS buffer
(1.5 mM EDTA, 1% FBS). Cells were passaged over a washed
MACS Column (Miltenyi) to remove aggregates, followed by a
CD45.2 MACS according to the manufacturer’s protocol. Puri-
ﬁed cells were stained with anti-CD11b-A700 (M1/70) and
CD45.2CCD11bC cells were subsequently FACsorted to homo-
geneity on a FACS Aria (BD) with a typical purity of >98%.
Quantitative PCR
CD45.2CCD11bC FACS-sorted cells were lysed and RNA was
isolated and quantiﬁed by spectrophotometry. cDNA was syn-
thesized using random primers and Moloney murine leukemia
virus Superscript Reverse Transcriptase (II-MMLV) (Invitro-
gen). Relative mRNA levels were determined with a Biorad
CFX96 cycler using the Fast Start SYBR Green Kit (Invitrogen).
Intron spanning primers (Sigma-Aldrich) were designed and
tested in our lab and are provided upon request Data were ana-
lyzed with Bio-rad CFX manager version 1.6 (Bio-rad) and
checked for correct ampliﬁcation and dissociation of the PCR-
products. PBGD and GUSB served as reference genes. mRNA
expression was determined relative to PBGD expression using
the formula 2(CT index – CT PBGD).
MTT assay
Cells were seeded in ﬂat-bottom 96-well plates (Costar) at 5 £
103 cells/well and cultured overnight to adhere. HDACi were
added to ﬁnal concentrations of 32, 256, 2048, and 16348 nM.
After 36 h incubation, medium was refreshed and 10 mL MTT
reagent (4 mg/mL) (Sigma) was added in PBS. Plates were incu-
bated for 2–4 h at 37C after which supernatant was removed
and 100 mL lysis buffer (0.5% SDS, 4% HCl, and 3.5% Milli-Q
in isopropanol) added. After 30 min of incubation, absorbance
was measured using an ELISA reader (Bio-Rad) at 595 nm.
Metabolic activity versus control was calculated as (treatment –
blank)/(control – blank) £ 100%. Triplicate wells for each con-
centration were performed.
Generation of NK/LAK effector cells
NK/LAK cells were generated from splenocytes of naive mice. A
10-mL syringe was ﬁlled with 1.2 g of Nylon Wool (Polysciences)
and sterilized. Five spleens were collected from 6–8 weeks old
naive female C57Bl/6 WT mice and single-cell suspensions were
made by passage over a 100 mm cell strainer. Ery-lysis was per-
formed using ACK-buffer and stopped with complete medium.
The nylon wool “column” was prepared using IMDM, containing
5% FCS, 1% AA, 2 mM Glutamine and 0.05% b-mercaptoetha-
nol (medium) for 1 h at RT. Splenocytes were passaged over a
nylon wool column and were plated at a density of 2.5 £ 106
cells/mL in medium containing 1000 IU/mL of human rIL-2. On
day 3 and 6, non-adherent cells were washed away by extensive
medium washings. On day 7, adherent cells were harvested using
1.5 mM EDTA. The harvested adherent cells were >90%
NK1.1CNKp46C cells, as determined by ﬂow cytometry.
Generation of bone marrow derived macrophages (BMDM)
Bone marrow cells were isolated from the femurs of 6–8 weeks
old female C57Bl/6 WT mice. 4 £ 106 bone marrow cells were
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cultured in a 10 cm2 petridish (Gibco) in medium supple-
mented with 20 ng/mL M-CSF (Peprotech). On day 3 and day
6, fresh M-CSF was added to the culture. When indicated,
20 ng/mL IL-4 (Peprotech) was added on day 6 to the BMDM
culture to obtain M2 BMDM. On day 7, the non-adherent cells
were discarded and washed away and adherent cells were har-
vested using cold 1.5 mM EDTA for experimental use.
FACS-based killing assay
9464D cells were incubated for 24 h in the presence of 256 nM
Vorinostat or control. 9464D (target) cells were harvested and
labeled with 1 mM CFSE (Invitrogen) according to the manu-
facturer’s protocol. Labeled target cells were plated at 20.000
cells/well in a ﬂat bottom 96-well plate. Target cells were pre-
incubated with medium containing 10 mg/mL anti-GD2 mAb
or isotype control for 1 h at 4C. Effector cells NK/LAK,
BMDM or BMDM treated with IL-4 for 24 h, were added in
effector: target cell ratios of 2:1, 4:1 and 6:1 for NK/LAK and
0,75:1, 1,5:1 and 3:1 for BMDM. After 8 h of co-culture, cells
were harvested and stained with 7-AAD (BD) and Annexin-V-
Cy5 (BD) according to the manufacturer’s protocol. Triplicate
samples were analyzed using a Cyan ﬂow cytometer and the
percentages of 7-AADC, Annexin-VC and 7-AADCAnnexin-
VC of CFSEC target cells were determined. Percentage speciﬁc
killing was calculated using the formula: (percentage of total
dead target cellstarget – percentage of total dead target cellscon-
trol)/(100 – percentage of total dead target cellscontrol) £ 100.
Immunohistoﬂuorescence
Mice bearing established 9464D tumors were treated Vorino-
stat or DMSO/PBS control after which tumors were excised
and snap frozen. Cryo-sections were made and directly ﬁxated
in ¡20C acetone. Sections were stained with anti-GD2-Cy5
mAb or isotype control mIgG2a-Cy5 (HOPC-1) for 1 h at RT.
Nuclear staining was performed using DAPI (Sigma) Sections
were imaged using a Leica DM ﬂuorescence microscope and
analyzed using ImageJ software.
Western blot analysis
9464D cells were incubated for 24 h with 0–2048nM Vorinostat
and lysed in lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM
TRIS pH 7.5 and 1% Triton X-100, 1£ protease inhibitor cock-
tail). For western blot analysis, samples were separated on 8%
SDS-PAGE resolving gels and transferred to PVDF mem-
branes. Membranes were incubated overnight at 4C with pri-
mary anti-GD2-Synthase (Novus Biologicals, Littleton, CO) or
anti-actin (Sigma-Aldrich, St. Louis, MO) antibodies in block-
ing buffer (1 £ PBS, 0.25% bovine serum albumin, 0.5% non-
fat dry milk). After washing with PBS-T (1 £ PBS, 0.1%
Tween-20), they were incubated with secondary IRDye 680LT-
conjugated polyclonal goat anti-rabbit IgG (H&L) antibody
(LI-COR, Lincoln, NE) in blocking buffer 1 h at RT. Mem-
branes were washed thoroughly with PBS-T, scanned with an
Odyssey infrared imaging system (LI-COR, Lincoln, NE) and
band intensities were quantiﬁed using ImageJ (NIH, Bethesda,
MD).
Statistics
Data were analyzed using Graphpad 5.0 software. An unpaired
T-test was used to determine signiﬁcant differences between
two groups. ANOVA test with a Bonferroni post-test was used
to determine signiﬁcant differences between three or more
groups. IC50s were calculated by ﬁtting log (inhibitor) – nor-
malized response curves.
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